TransMedics Group, Inc. (TMDX) Net Profit Margin: 27.04%
Is TransMedics Group, Inc.’s net profit margin high or low?
TransMedics Group, Inc.'s net profit margin of 27.04% is 161% above its 5-year average of -44.65%, near the high end of its 5-year range (-146.11%–31.43%).
As of Saturday, June 20, 2026. 37.05% above its 12-month average of 19.73%.
TMDX Net Profit Margin Chart
TMDX Average Net Profit Margin Chart
TMDX Current vs Average Net Profit Margin Chart
TMDX Net Profit Margin Metrics
NET PROFIT MARGIN
27.04%
NET PROFIT MARGIN AVG TTM
19.73%
NET PROFIT MARGIN AVG 3Y
-2.42%
NET PROFIT MARGIN AVG 5Y
-44.65%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+37.05%
CURRENT VS 3Y AVG
+1218.51%
CURRENT VS 5Y AVG
+160.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 27.04% | 19.73% | -2.42% | -44.65% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | -17.06% | -20.12% | -16.95% | -10.04% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -134.54% | -225.74% | -158.88% | -132.14% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 6.52% | -21.22% | -48.94% | 16.61% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | -0.56% | 7.00% | -0.29% | -8.82% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | -22.20% | -60.53% | -62.93% | -77.31% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | -4.59% | -1.67% | 5.09% | 7.31% |
| Baxter International Inc. (BAX)vs › | $10.27B | -9.70% | -7.30% | -3.29% | 1.14% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -4.07% | -4.03% | -0.72% | 0.14% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 8.30% | 9.60% | 8.02% | 12.66% |
Margin Comparison
Operating Margin
14.8%
Net Profit Margin
27.0%
TransMedics Group, Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Net Profit Margin FAQ
- What is the net profit margin for TransMedics Group, Inc. (TMDX)?
- The net profit margin for TMDX stock is 27.04%.
- Is TransMedics Group, Inc.'s net profit margin high or low?
- TransMedics Group, Inc.'s net profit margin of 27.04% is 161% above its 5-year average of -44.65%, near the high end of its 5-year range (-146.11%–31.43%).
- What is the TTM average net profit margin for TransMedics Group, Inc. (TMDX)?
- The TTM average net profit margin for TMDX stock is 19.73%.
- What is the 3Y average net profit margin for TransMedics Group, Inc. (TMDX)?
- The 3Y average net profit margin for TMDX stock is -2.42%.
- What is the 5Y average net profit margin for TransMedics Group, Inc. (TMDX)?
- The 5Y average net profit margin for TMDX stock is -44.65%.
TransMedics Group, Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 31.43% |
| 2024-12-31 | 8.03% |
| 2023-12-31 | -10.36% |
| 2022-12-31 | -38.77% |
| 2021-12-31 | -146.11% |
| 2020-12-31 | -112.13% |
| 2019-12-31 | -142.12% |
| 2018-12-31 | -182.50% |
| 2017-12-31 | -270.96% |
| 2016-12-31 | -387.58% |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein